About
About Shionogi
Our leadership team
History and values
Global affiliates and locations
Investor relations
Sustainability
Sustainability
Tax strategy
Transparency
Governance, policies and position statements
Innovation
Innovation
Our areas of focus
Strategic partnering in Europe
Global innovation
Grants and donations
News
Investors
Careers
Contact
Europe
Worldwide
Home
News
Press Releases
Shionogi Receives Approvals of Paediatric Use and Additional Indication for Purulent Meningitis of Carbapenem-Type Antibiotic,"Finibax® 0.25g/0.5g for Intravenous Drip Infusion" and "Finibax® 0.25g Kit for Intravenous Drip Infusion"
Release
Medical News
2012/05/25
Shionogi Receives Approvals of Paediatric Use and Additional Indication for Purulent Meningitis of Carbapenem-Type Antibiotic,"Finibax® 0.25g/0.5g for Intravenous Drip Infusion" and "Finibax® 0.25g Kit for Intravenous Drip Infusion"
